Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2011

01-12-2011 | Review

β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer

Authors: Hicham Lahlou, William J Muller

Published in: Breast Cancer Research | Issue 6/2011

Login to get access

Abstract

Consistent with their essential role in cell adhesion to the extracellular matrix, integrins and their associated signaling pathways have been shown to be involved in cell proliferation, migration, invasion and survival, processes required in both tumorigenesis and metastasis. β1-integrins represent the predominantly expressed integrins in mammary epithelial cells and have been proven crucial for mammary gland development and differentiation. Here we provide an overview of the studies that have used transgenic mouse models of mammary tumorigenesis to establish β1-integrin as a critical mediator of breast cancer progression and thereby as a potential therapeutic target for the development of new anticancer strategies.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010, 19: 1893-1907. 10.1158/1055-9965.EPI-10-0437.PubMedCrossRef
2.
Sadikovic B, Al-Romaih K, Squire JA, Zielenska M: Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 2008, 9: 394-408. 10.2174/138920208785699580.PubMedPubMedCentralCrossRef
3.
Guarneri V, Conte P: Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009, 14: 645-656. 10.1634/theoncologist.2009-0078.PubMedCrossRef
4.
Allred DC, Medina D: The relevance of mouse models to understanding the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia. 2008, 13: 279-288. 10.1007/s10911-008-9093-5.PubMedCrossRef
5.
Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM: Molecular interactions in cancer cell metastasis. Acta Histochem. 2010, 112: 3-25. 10.1016/j.acthis.2008.11.022.PubMedCrossRef
6.
Guo W, Giancotti FG: Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004, 5: 816-826. 10.1038/nrm1490.PubMedCrossRef
7.
Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell. 2002, 110: 673-687. 10.1016/S0092-8674(02)00971-6.PubMedCrossRef
8.
Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B: Functional atlas of the integrin adhesome. Nat Cell Biol. 2007, 9: 858-867. 10.1038/ncb0807-858.PubMedPubMedCentralCrossRef
9.
Legate KR, Wickstrom SA, Fassler R: Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 2009, 23: 397-418. 10.1101/gad.1758709.PubMedCrossRef
10.
Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010, 10: 9-22. 10.1038/nrc2748.PubMedPubMedCentralCrossRef
11.
12.
Luo BH, Carman CV, Springer TA: Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007, 25: 619-647. 10.1146/annurev.immunol.25.022106.141618.PubMedPubMedCentralCrossRef
13.
Arnaout MA, Goodman SL, Xiong JP: Structure and mechanics of integrinbased cell adhesion. Curr Opin Cell Biol. 2007, 19: 495-507. 10.1016/j.ceb.2007.08.002.PubMedPubMedCentralCrossRef
14.
Huveneers S, Danen EH: Adhesion signaling - crosstalk between integrins, Src and Rho. J Cell Sci. 2009, 122 (Pt 8): 1059-1069.PubMedCrossRef
15.
Soung YH, Clifford JL, Chung J: Crosstalk between integrin and receptor tyrosine kinase signaling in breas t carcinoma progression. BMB Rep. 2010, 43: 311-318. 10.5483/BMBRep.2010.43.5.311.PubMedCrossRef
16.
Caswell PT, Vadrevu S, Norman JC: Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol. 2009, 10: 843-853. 10.1038/nrm2799.PubMedCrossRef
17.
Brakebusch C, Fassler R: Beta1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev. 2005, 24: 403-411. 10.1007/s10555-005-5132-5.PubMedCrossRef
18.
Taddei I, Faraldo MM, Teuliere J, Deugnier MA, Thiery JP, Glukhova MA: Integrins in mammary gland development and differentiation of mammary epithelium. J Mammary Gland Biol Neoplasia. 2003, 8: 383-394.PubMedCrossRef
19.
Aszodi A, Hunziker EB, Brakebusch C, Fassler R: Beta1 integrins regulate chondrocyte rotation, G1 progress ion, and cytokinesis. Genes Dev. 2003, 17: 2465-2479. 10.1101/gad.277003.PubMedPubMedCentralCrossRef
20.
Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ: Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol. 2001, 152: 1207-1218. 10.1083/jcb.152.6.1207.PubMedPubMedCentralCrossRef
21.
Schwander M, Leu M, Stumm M, Dorchies OM, Ruegg UT, Schittny J, Muller U: β1 integrins regulate myoblast fusion and sarcomere assembly. Dev Cell. 2003, 4: 673-685. 10.1016/S1534-5807(03)00118-7.PubMedCrossRef
22.
Brakebusch C, Grose R, Quondamatteo F, Ramirez A, Jorcano JL, Pirro A, Svensson M, Herken R, Sasaki T, Timpl R, Werner S, Fassler R: Skin and hair follicle integrity is crucially dependent on beta 1 integrin expression on keratinocytes. EMBO J. 2000, 19: 3990-4003. 10.1093/emboj/19.15.3990.PubMedPubMedCentralCrossRef
23.
Belvindrah R, Graus-Porta D, Goebbels S, Nave KA, Muller U: Beta1 integrins in radial glia but not in migrating neurons are essential for the formation of cell layers in the cerebral cortex. J Neurosci. 2007, 27: 13854-13865. 10.1523/JNEUROSCI.4494-07.2007.PubMedCrossRef
24.
Mettouchi A, Menegu zzi G: Distinct roles of β1 integrins during angiogenesis. Eur J Cell Biol. 2006, 85: 243-247. 10.1016/j.ejcb.2005.09.010.PubMedCrossRef
25.
Anderson R, Fassler R, Georges-Labouesse E, Hynes RO, Bader BL, Kreidberg JA, Schaible K, Heasman J, Wylie C: Mouse primordial germ cells lacking β1 integrins enter the germline but fail to migrate normally to the gonads. Development. 1999, 126: 1655-1664.PubMed
26.
Fassler R, Meyer M: Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995, 9: 1896-1908. 10.1101/gad.9.15.1896.PubMedCrossRef
27.
Stephens LE, Sutherla nd AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA, Damsky CH: Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev. 1995, 9: 1883-1895. 10.1101/gad.9.15.1883.PubMedCrossRef
28.
Legate KR, Fassler R: Mechanisms that regulate adaptor binding to betaintegrin cytoplasmic tails. J Cell Sci. 2009, 122 (Pt 2): 187-198.PubMedCrossRef
29.
Liu S, Calderwood DA, Ginsberg MH: Integrin cytoplasmic domain-binding proteins. J Cell Sci. 2000, 113 (Pt 20): 3563-3571.PubMed
30.
Regent M, Planus E, B ouin AP, Bouvard D, Brunner M, Faurobert E, Millon-Fremillon A, Block MR, Albiges-Rizo C: Specificities of beta(1) integrin signaling in the control of cell adhesion and adhesive strength. Eur J Cell Biol. 2011, 90: 261-269. 10.1016/j.ejcb.2010.09.006.PubMedCrossRef
31.
Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005, 6: 56-68. 10.1038/nrm1549.PubMedCrossRef
32.
Wennerberg K, Armulik A, Sakai T, Karlsson M, Fassler R, Schaefer EM, Mosher DF, Johansson S: The cytoplasmic tyrosines of integrin subunit β1 are involved in focal adhesion kinase activation. Mol Cell Biol. 2000, 20: 5758-5765. 10.1128/MCB.20.15.5758-5765.2000.PubMedPubMedCentralCrossRef
33.
Schaller MD, Otey CA, Hildebrand JD, Parsons JT: Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol. 1995, 130: 1181-1187. 10.1083/jcb.130.5.1181.PubMedCrossRef
34.
Brown MC, Turner CE: Paxillin: adapting to change. Physiol Rev. 2004, 84: 1315-1339. 10.1152/physrev.00002.2004.PubMedCrossRef
35.
Thomas JW, Cooley MA, Broome JM, Salgia R, Griffin JD, Lombardo CR, Schaller MD: The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999, 274: 36684-36692. 10.1074/jbc.274.51.36684.PubMedCrossRef
36.
Mitra SK, Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006, 18: 516-523. 10.1016/j.ceb.2006.08.011.PubMedCrossRef
37.
Playford MP, Schaller MD: The interplay between Src and integrins in normal and tumor biology. Oncogene. 2004, 23: 7928-7946. 10.1038/sj.onc.1208080.PubMedCrossRef
38.
Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, Cheresh DA, Schlaepfer DD: Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene. 2006, 25: 5969-5984. 10.1038/sj.onc.1209588.PubMedCrossRef
39.
Xia H, Nho RS, Kahm J, Kleidon J, Henke CA: Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem. 2004, 279: 33024-33034. 10.1074/jbc.M313265200.PubMedCrossRef
40.
Gustavsson A, Yuan M, Fallman M: Temporal dissection of β1-integrin signaling indicates a role for p130Cas-Crk in filopodia formation. J Biol Chem. 2004, 279: 22893-22901. 10.1074/jbc.M309693200.PubMedCrossRef
41.
Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH: Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol. 2000, 149: 741-754. 10.1083/jcb.149.3.741.PubMedPubMedCentralCrossRef
42.
Klinowska TC, Soriano J V, Edwards GM, Oliver JM, Valentijn AJ, Montesano R, Streuli CH: Laminin and β1 integrins are crucial for normal mammary gland development in the mouse. Dev Biol. 1999, 215: 13-32. 10.1006/dbio.1999.9435.PubMedCrossRef
43.
Li N, Zhang Y, Naylor MJ, Schatzmann F, Maurer F, Wintermantel T, Schuetz G, Mueller U, Streuli CH, Hynes NE: Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J. 2005, 24: 1942-1953. 10.1038/sj.emboj.7600674.PubMedPubMedCentralCrossRef
44.
Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R, Wang P, Schatzmann F, Wintermantel T, Schuetz G, Clarke AR, Mueller U, Hynes NE, Streuli CH: Ablation of β1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol. 2005, 171: 717-728. 10.1083/jcb.200503144.PubMedPubMedCentralCrossRef
45.
Pontier SM, Muller WJ: Integrins in mammary-stem-cell biology and breastcancer progression - a role in cancer stem cells?. J Cell Sci. 2009, 122 (Pt 2): 207-214.PubMedCrossRef
46.
Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, Medina D, Fassler R, Thiery JP, Glukhova MA: Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol. 2008, 10: 716-722. 10.1038/ncb1734.PubMedPubMedCentralCrossRef
47.
Shaw LM: Integrin function in breast carcinoma progression. J Mammary Gland Biol Neoplasia. 1999, 4: 367-376. 10.1023/A:1018766317055.PubMedCrossRef
48.
Litjens SH, de Pereda JM, S onnenberg A: Current insights into the formation and breakdown of hemidesmosomes. Trends Cell Biol. 2006, 16: 376-383. 10.1016/j.tcb.2006.05.004.PubMedCrossRef
49.
Woodward TL, Mienaltowski A S, Modi RR, Bennett JM, Haslam SZ: Fibronectin and the alpha(5)beta(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology. 2001, 142: 3214-3222. 10.1210/en.142.7.3214.PubMed
50.
Novaro V, Roskelley CD, Bissell MJ: Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci. 2003, 116 (Pt 14): 2975-2986.PubMedPubMedCentralCrossRef
51.
Gardner H, Kreidberg J, Koteliansky V, Jaenisch R: Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev Biol. 1996, 175: 301-313. 10.1006/dbio.1996.0116.PubMedCrossRef
52.
Klinowska TC, Alexander CM, Georges-Labouesse E, Vander Neut R, Kreidberg JA, Jones CJ, Sonnenberg A, Streuli CH: Epithelial development and differentiation in the mammary gland is not dependent on alpha 3 or alpha 6 integrin subunits. Dev Biol. 2001, 233: 449-467. 10.1006/dbio.2001.0204.PubMedCrossRef
53.
Chen J, Diacovo TG, Grenach e DG, Santoro SA, Zutter MM: The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol. 2002, 161: 337-344. 10.1016/S0002-9440(10)64185-5.PubMedPubMedCentralCrossRef
54.
Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, Muller WJ: Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA. 2007, 104: 20302-20307. 10.1073/pnas.0710091104.PubMedPubMedCentralCrossRef
55.
White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ: Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 2004, 6: 159-170. 10.1016/j.ccr.2004.06.025.PubMedCrossRef
56.
Jones JL, Critchley DR, Walker RA: Alteration of stromal protein and integrin expression in breast - a marker of premalignant change?. J Pathol. 1992, 167: 399-406. 10.1002/path.1711670409.PubMedCrossRef
57.
Jonjic N, Lucin K, Krstulja M, Iternicka Z, Mustac E: Expression of beta-1 integrins on tumor cells of invasive ductal breast carcinoma. Pathol Res Pract. 1993, 189: 979-984. 10.1016/S0344-0338(11)80668-0.PubMedCrossRef
58.
Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould VE: Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol. 1991, 139: 787-799.PubMedPubMedCentral
59.
Pignatelli M, Cardillo MR, Hanby A, Stamp GW: Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol. 1992, 23: 1159-1166. 10.1016/0046-8177(92)90034-Z.PubMedCrossRef
60.
Zutter MM, Krigman HR, Santoro SA: Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol. 1993, 142: 1439-1448.PubMedPubMedCentral
61.
Berry MG, Gui GP, Wells CA, Carpenter R: Integrin expression and survival in human breast cancer. Eur J Surg Oncol. 2004, 30: 484-489. 10.1016/j.ejso.2004.01.016.PubMedCrossRef
62.
Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, Nicholson RI, Robertson JF, Blamey RW, Ellis IO: An immunohistochemical examination of the expression of E-cadherin, α- and β/γ-catenins, and α2- and β1-integrins in invasive breast cancer. J Pathol. 1999, 187: 523-529. 10.1002/(SICI)1096-9896(199904)187:5<523::AID-PATH296>3.0.CO;2-3.PubMedCrossRef
63.
Berry MG, Goode AW, Puddefoot J R, Vinson GP, Carpenter R: Integrin β1-mediated invasion of human breast cancer cells: an ex vivo assay for invasiveness. Breast Cancer. 2003, 10: 214-219. 10.1007/BF02966720.PubMedCrossRef
64.
Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ: Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006, 66: 1526-1535. 10.1158/0008-5472.CAN-05-3071.PubMedPubMedCentralCrossRef
65.
Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997, 137: 231-245. 10.1083/jcb.137.1.231.PubMedPubMedCentralCrossRef
66.
Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C: Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007, 67: 659-664. 10.1158/0008-5472.CAN-06-2768.PubMedCrossRef
67.
Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, Abdulkarim B: Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 2009, 69: 8620-8628. 10.1158/0008-5472.CAN-09-1591.PubMedCrossRef
68.
Golubovskaya VM, Kweh FA, Cance W G: Focal adhesion kinase and cancer. Histol Histopathol. 2009, 24: 503-510.PubMed
69.
Watermann DO, Gabriel B, Jager M, Orlowska-Volk M, Hasenburg A, zur Hausen A, Gitsch G, Stickeler E: Specific induction of pp125 focal adhesion kinase in human breast cancer. Br J Cancer. 2005, 93: 694-698. 10.1038/sj.bjc.6602744.PubMedPubMedCentralCrossRef
70.
Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, Choueiri TK, Crowe JP, Tubbs RR, Budd TG, Hicks DG: The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Breast J. 2007, 13: 130-139. 10.1111/j.1524-4741.2007.00389.x.PubMedCrossRef
71.
Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC: The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res. 2004, 10 (18 Pt 1): 6194-6202.PubMedCrossRef
72.
Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW: Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003, 163: 2113-2126. 10.1016/S0002-9440(10)63568-7.PubMedPubMedCentralCrossRef
73.
Marcotte R, Muller WJ: Signal transduction in transgenic mouse models of human breast cancer - implications for human breast cancer. J Mammary Gland Biol Neoplasia. 2008, 13: 323-335. 10.1007/s10911-008-9087-3.PubMedCrossRef
74.
Pontier SM, Muller WJ: Integrins in breast cancer dormancy. APMIS. 2008, 116: 677-684. 10.1111/j.1600-0463.2008.01026.x.PubMedCrossRef
75.
Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL: Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009, 69: 466-474. 10.1158/0008-5472.CAN-08-3078.PubMedPubMedCentralCrossRef
76.
Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ: Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol. 2008, 173: 1551-1565. 10.2353/ajpath.2008.080308.PubMedPubMedCentralCrossRef
77.
Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG: Rasand PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest. 2009, 119: 252-266.PubMedPubMedCentral
78.
Eccles SA: The role of c-erbB-2/H ER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia. 2001, 6: 393-406. 10.1023/A:1014730829872.PubMedCrossRef
79.
Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ: Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer. 2007, 7: 389-397. 10.1038/nrc2127.PubMedCrossRef
80.
Huck L, Pontier SM, Zuo DM, Muller WJ: Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA. 2010, 107: 15559-15564. 10.1073/pnas.1003034107.PubMedPubMedCentralCrossRef
81.
Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, Pawson T, Muller WJ: ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J. 2008, 27: 910-920. 10.1038/emboj.2008.22.PubMedPubMedCentralCrossRef
82.
Moro L, Dolce L, Cabodi S, Bergatto E, Boeri Erba E, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M, Godovac-Zimmermann J, Conti A, Schaefer E, Beguinot L, Tacchetti C, Gaggini P, Silengo L, Tarone G, Defilippi P: Integrininduced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem. 2002, 277: 9405-9414. 10.1074/jbc.M109101200.PubMedCrossRef
83.
Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC: Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol. 2008, 183: 143-155. 10.1083/jcb.200804140.PubMedPubMedCentralCrossRef
84.
Liu Y, Pixley R, Fusaro M, Godoy G, Kim E, Bromberg ME, Colman RW: Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene. 2009, 28: 2756-2765. 10.1038/onc.2009.132.PubMedPubMedCentralCrossRef
85.
Tagliabue E, Ghirelli C, Squicciarini P, Aiello P, Colnaghi MI, Menard S: Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin Cancer Res. 1998, 4: 407-410.PubMed
86.
Chung J, Mercurio AM: Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol Cells. 2004, 17: 203-209.PubMed
87.
Gilcrease MZ, Zhou X, Lu X, Woodwar d WA, Hall BE, Morrissey PJ: Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res. 2009, 28: 67-76. 10.1186/1756-9966-28-67.PubMedPubMedCentralCrossRef
88.
Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG: Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 2006, 126: 489-502. 10.1016/j.cell.2006.05.047.PubMedCrossRef
89.
Pontier SM, Huck L, White DE, Rayment J, Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB, Dedhar S, Marshall CJ, Muller WJ: Integrinlinked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene. 2010, 29: 3374-3385. 10.1038/onc.2010.86.PubMedCrossRef
90.
Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P: p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 2006, 66: 4672-4680. 10.1158/0008-5472.CAN-05-2909.PubMedCrossRef
91.
Taverna D, Crowley D, Connolly M, Bronson RT, Hynes RO: A direct test of potential roles for β3 and β5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res. 2005, 65: 10324-10329. 10.1158/0008-5472.CAN-04-4098.PubMedCrossRef
92.
Ramirez NE, Zhang Z, Madamanchi A, Bo yd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM: The αβ integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest. 2011, 121: 226-237. 10.1172/JCI42328.PubMedCrossRef
93.
Yoshimura K, Meckel KF, Laird LS, Chia CY, Park JJ, Olino KL, Tsunedomi R, Harada T, Iizuka N, Hazama S, Kato Y, Keller JW, Thompson JM, Chang F, Romer LH, Jain A, Iacobuzio-Donahue C, Oka M, Pardoll DM, Schulick RD: Integrin α2 mediates selective metastasis to the liver. Cancer Res. 2009, 69: 7320-7328. 10.1158/0008-5472.CAN-09-0315.PubMedPubMedCentralCrossRef
94.
Cox D, Brennan M, Moran N: Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010, 9: 804-820. 10.1038/nrd3266.PubMedCrossRef
95.
Bhaskar V, Zhang D, Fox M, Seto P, Wong M H, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V: A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med. 2007, 5: 61-71. 10.1186/1479-5876-5-61.PubMedPubMedCentralCrossRef
96.
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ: A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011, 121: 273-279. 10.1016/j.ygyno.2010.12.362.PubMedPubMedCentralCrossRef
97.
Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, DuBridge RB, Ramakrishnan V: Volociximab, a chimeric integrin α5β1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008, 26: 7-12. 10.1007/s10637-007-9078-z.PubMedCrossRef
98.
Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP: Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a Ushaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res. 2008, 14: 2137-2144. 10.1158/1078-0432.CCR-07-4530.PubMedCrossRef
99.
Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Donate F, Shaw DE, Mazar AP, Rabbani SA: A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006, 5: 2271-2280. 10.1158/1535-7163.MCT-06-0100.PubMedCrossRef
100.
Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM: Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003, 104: 496-503. 10.1002/ijc.10958.PubMedCrossRef
101.
Nam JM, Chung Y, Hsu HC, Park CC: Beta1 integrin targeting to enhance radiation therapy. Int J Radiat Biol. 2009, 85: 923-928. 10.3109/09553000903232876.PubMedCrossRef
102.
Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ: Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008, 68: 4398-4405. 10.1158/0008-5472.CAN-07-6390.PubMedPubMedCentralCrossRef
103.
Faschinger A, Rouault F, Sollner J, Lukas A, Salmons B, Gunzburg WH, Indik S: Mouse mammary tumor virus integration site selection in human and mouse genomes. J Virol. 2008, 82: 1360-1367. 10.1128/JVI.02098-07.PubMedCrossRef
104.
Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ: Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA. 2000, 97: 3444-3449. 10.1073/pnas.050408497.PubMedPubMedCentralCrossRef
105.
Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G: Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008, 14: 7924-7929. 10.1158/1078-0432.CCR-08-0378.PubMedPubMedCentralCrossRef
106.
Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB: Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer. 2006, 94: 1621-1626.PubMedPubMedCentral
Metadata
Title
β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer
Authors
Hicham Lahlou
William J Muller
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2905

Other articles of this Issue 6/2011

Breast Cancer Research 6/2011 Go to the issue

Research article

Variants on the promoter region of PTEN affect breast cancer progression and patient survival

Review

Clinical relevance and biology of circulating tumor cells

Research article

Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion

Research article

Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis

Research article

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

Review

Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits